Business Context and Reporting Period
Company: CAMP4 Therapeutics Corp (CAMP)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: CAMP4 is a clinical-stage biopharmaceutical company developing RNA-targeting therapeutics to upregulate gene expression for genetic diseases. The company focuses on the central nervous system (CNS), with its lead candidate, CMP-002, targeting SYNGAP1-related disorder. It utilizes a proprietary RAP Platform to identify regulatory RNAs (regRNAs). The company has no approved products and has not generated revenue from product sales.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Revenue | $3,498 | $652 |
| Net Loss | $(80,403) | $(51,791) |
| Research & Development Expenses | $38,202 | $38,817 |
| General & Administrative Expenses | $17,357 | $14,923 |
| Cash and Cash Equivalents (Year End) | $109,517 | $64,039 |
| Accumulated Deficit | $(292,156) | $(211,753) |
| Net Cash Used in Operating Activities | $(29,553) | $(45,562) |
Note: The 2025 Net Loss includes a non-cash charge of $29.8 million related to the change in fair value of a derivative tranche liability.
Material Changes vs. Prior Period
- Revenue Increase: Revenue increased by $2.8 million (436%) primarily due to $2.2 million in revenue from the BioMarin collaboration and a $0.6 million milestone payment from Fulcrum Therapeutics.
- Net Loss Expansion: Net loss increased by $28.6 million. This was driven largely by a $29.8 million non-cash loss on the derivative tranche liability associated with a September 2025 private placement, partially offset by higher interest income.
- Operating Expenses: Total operating expenses increased by $2.3 million. G&A expenses rose by $2.4 million due to professional fees and issuance costs related to equity financings. R&D expenses decreased slightly by $0.6 million due to a strategic decision to pause investment in the CMP-001 (Urea Cycle Disorders) program.
- Liquidity: Cash and cash equivalents increased by $45.5 million, funded by $76.0 million in net proceeds from equity offerings (September private placement and December underwritten offering).
Guidance, Outlook, and Risks
Outlook and Guidance:
- Cash Runway: Management estimates that as of December 31, 2025, cash and cash equivalents of $109.5 million are sufficient to fund operations into 2028.
- Clinical Timeline: The company intends to initiate a global Phase 1/2 clinical trial for CMP-002 (SYNGAP1) as early as the second half of 2026, pending successful GLP toxicology studies and regulatory clearance.
- Strategic Shift: The company paused new investment in the CMP-001 program in Q2 2025 to prioritize the SYNGAP1 program and is seeking partnership opportunities for CMP-001.
Management Commentary:
- GSK Collaboration: In December 2025, the company entered a Research, Collaboration, and License Agreement with GlaxoSmithKline (GSK) for neurodegenerative and kidney disease indications. GSK paid a $17.5 million upfront payment, with potential milestones up to $440 million. No revenue was recognized from this agreement in 2025 as work is expected to begin in 2026.
- Facilities: The company vacated its Boulder, Colorado facility in August 2025, resulting in a $0.5 million impairment charge. It is relocating to a new 44,000 sq. ft. facility in Watertown, Massachusetts, commencing in 2026.
Risks and Contingencies:
- Capital Requirements: The company expects to incur significant losses for the foreseeable future and will require substantial additional capital to advance clinical trials and commercialization.
- Derivative Liability: The company has a derivative tranche liability of $44.8 million related to a conditional second closing of a private placement, which is subject to fair value remeasurement and could impact future earnings.
- Regulatory and Development Risk: Success depends on the safety and efficacy of product candidates, which are in preclinical or early clinical stages. There is no guarantee of regulatory approval.
- Supply Chain: The company relies on third-party manufacturers, including a Chinese supplier for raw materials, which poses risks related to the BIOSECURE Act and trade policies.
Key Facts for Investor Verification
- Derivative Liability Impact: Verify the specific triggers for the $44.8 million derivative tranche liability (stock price threshold of $7.50 and regulatory milestones) and the probability-weighted assumptions used for valuation.
- Cash Burn Rate: Confirm the projected operating expenses for 2026 and 2027 to validate the "into 2028" cash runway estimate, especially given the upcoming Phase 1/2 trial initiation.
- GSK Revenue Recognition: Monitor the timing of revenue recognition for the $17.5 million GSK upfront payment, which is currently recorded as deferred revenue and will be recognized over time as R&D activities commence in 2026.
- CMP-001 Status: Verify the status of partnership discussions for the paused CMP-001 program and any potential asset sales or licensing deals.
- Patent Portfolio: Note that the company does not currently own or in-license any issued patents directed to the composition of matter of its lead candidate, CMP-002; verify the status of pending applications.